Nature’s Toolbox, Inc. to Participate in the 2022 BIO International Convention

RIO RANCHO, N.M.--(BUSINESS WIRE)--Nature's Toolbox, Inc. (NTx), a life sciences company enabling novel RNA product development, today announced that several of its executives will attend the Biotechnology Innovation Organization (BIO) International Convention taking place at the San Diego Convention Center from Monday, June 13 – Thursday, June 16, 2022.

NTx is a leader in producing high quality extended length mRNA and saRNA transcripts. Its cell-free, continuous-flow process mitigates the typical development challenges by producing extended length material and helps accelerate pre-clinical candidates towards regulatory filings and clinical studies.

BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and in 30+ countries. 2022 BIO International Congress will hold more than 100 interactive meetings in 4 days, covering a variety of therapeutic areas, business development, digital health, patient advocacy, public policy, and next generation biotherapies, as well as industry experts’ latest updates and vaccines to COVID-19.

At the conference, Dr. Alexander Koglin, CEO, and co-founder of NTx will deliver a presentation:

• "Nature's Toolbox, Inc: IVT technology to accelerate the next generations of RNA product development"
  • Wednesday, June 15 at 11:15am PT
  • Theatre 3

To see the full conference schedule and to register for the convention please click here.

To set up time to meet with the NTx team at the conference, please send a request through the BIO partnering system here, or come by booth #1937 in the NM Pavilion.

If you are not attending the conference and would like to learn more about NTx, please email info@ntxbio.com.

To learn more about NTx and its proprietary platform, please visit: https://www.ntxbio.com.

About NTx

Nature's Toolbox, Inc. (NTx) is a life sciences company located in Rio Rancho, New Mexico. The company is commercializing its biomanufacturing systems NTxpress®, NTxscribe® and the bioinformatics platform, DruID, for the discovery of natural products. NTx’s proprietary continuous-flow, fully recombinant, in vitro, cell-free transcription system utilizes hollow fiber bioreactors to support the growing demand for mRNA-based vaccines and therapeutics. NTx’s biomanufacturing processes can easily be scaled to meet fluctuating supply needs so that companies can increase and streamline production as they respond to changing global demands. For more information, please visit: https://www.ntxbio.com

Media
Kalyn Kolek, kos@anzupartners.com